Phase I study of oral topotecan in hematological malignancies

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4084-4091

  Beran, Miloslav ^a   O'Brien, Susan ^a   Thomas, Deborah A ^a   Tran, Hai T ^a   Cortes Franco, Jorge E ^a   Giles, Francis ^a   Estey, Elihu ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DEATH; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKOCYTE COUNT; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEUTROPHILS; PLATELET COUNT; TOPOTECAN;

EID: 0141455145     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
2. von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., Carmichael, J., Krebs, J. B., Ross, G., Lane, S. R., and Gralla, R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol., 17: 658-667, 1999.
3. Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., and Verweij, J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol., 15: 2090-2096, 1997.
4. ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., Bolis, G., Malmström, H., Coleman, R., Fields, S. C., and Heron, J. F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 15: 2183-2193, 1997.
5. Bookman, M. A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J. B., and Fields, S. Z. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol., 16: 3345-3352, 1998.
6. Kantarjian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M. B., Plunkett, W., and Keating, M. J. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81: 1146-1151, 1993.
7. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y. C., Grochow, L. B., and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
8. Rowinsky, E. K., Kaufmann, S. H., Baker, S. D., Miller, C. B., Sartorius, S. E., Bowling, M. K., Chen, T. L., Donehower, R. C., and Gore, S. D. A Phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clin. Cancer Res., 2: 1921-1930, 1996.
9. Beran, M., Kantarjian, H., O'Brien, S., Koller, C., Albitar, M., Arbuck, S., Pierce, S., Moore, M., Abbruzzese, J. L., Andreeff, M., Keating, M., and Estey, E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 88: 2473-2479, 1996.
10. Beran, M., Estey, E., O'Brien, S., Cortes, J., Koller, C. A., Giles, F. J., Kornblau, S., Andreeff, M., Vey, N., Pierce, S. R., Hayes, K., Wong, G. C., Keating, M., and Kantarjian, H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin. Oncol., 17: 2819-2830, 1999.
11. Schellens, J. H. M., Creemers, G. J., Beijnen, J. H., Rosing, H., DeBoer-Denner, M., McDonald, M., Davies, B., and Verweij, J., Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer, 73: 1268-1271, 1996.
12. Herben, V. M. M., Rosing, H., Ten Bokkel Huinink, W. W., Van Zoomeren, D. M., Batchelor, D., Doyle, E., Beusenberg, F. B., Beijnen, J. H., and Schellens, J. H. M. Oral topotecan: bioavailability and effect of food co-administration. Br. J. Cancer, 80: 1380-1386, 1999.
13. Gerrits, C. J. H., Burris, H., Schellens, J. H. M., Planting, A. S. T., van den Burg, M. E. L., Rodriguez, G. I., van Beurden, V., Loos, W. J., Hudson, I., Fields, S., Verweij, J., and von Hoff, D. D. Five days of oral topotecan (Hycamtin®), a Phase I and pharmacological study in adult patients with solid tumors. Eur. J. Cancer, 34: 1030-1035, 1998.
14. Loos, W. J., Gelderblom, H., Sparreboom, A., Verweij, J., and de Jonge, M. J. A. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin. Cancer Res., 6: 2685-2689, 2000.
15. Zamboni, W. C., Bowman, L. C., Tan, M., Santana, V. M., Houghton, P. J., Meyer, W. H., Pratt, C. B., Heideman, R. L., Gajjar, A. J., Pappo, A. S., and Stewart, C. F. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother. Pharmacol., 43: 454-460, 1999.
16. Loos, W. J., Stoter, G., Verweij, J., and Schellens, J. H. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. J. Chromatogr. B. Biomed. Appl., 678: 309-315, 1996.
17. Creemers, G. J., Gerrits, C. J., Eckardt, J. R., Schellens, J. H., Burris, H. A., Planting, A. S., Rodriguez, G. I., Loos, W. J., Hudson, I., Broom, C., Verweij, J., and Von Hoff, D. D. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J. Clin. Oncol., 15: 1087-1093, 1997.
18. von Pawel, J., Gatzemeier, U., Pujol, J. L., Moreau, L., Bildat, S., Ranson, M., Richardson, G., Steppert, C., Riviere, A., Camlett, I., Lane, S., and Ross, G. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J. Clin. Oncol., 19: 1743-1749, 2001.
19. Bennett, J. M. Classification of the myelodysplastic syndromes. Clin. Haematol., 15: 909-923, 1986.
20. Beran, M., Cortes, J. E., O'Brien, S., Thomas, D. A., Onida, F., and Estey, E. Phase I study of prolonged administration of oral topotecan in hematological malignancies. Blood, 98: 642a, 2001.
21. Van Warmerdam, L. J., Verweij, J., Schellens, J. H., Rosing, H., Davies, B. E., de Boer-Denert, M., Maes, R. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
22. Stewart, C. F., Zamboni, W. C., Crom, W. R., Gajjar, A., Heideman, R. L., Furman, W. L., Meyer, W. H., Houghton, P. J., and Pratt, C. B., Topoisomerase I interactive drugs in children with cancer. Investig. New Drugs, 14: 37-47, 1996.
23. Bowman, L. C., Stewart, C. F., Zamboni, W. C., Crom, W. R., Luo, X., Heideman, R., Houghton, P. J., Meyer, W. H., and Pratt, C. B. Toxicity and pharmacodynamics of oral topotecan (POTOPO) in pediatric patients with relapsed solid tumors. Proc. Am. Soc. Clin. Oncol., 15: 462, 1996.
24. Grinblatt, D. L., Yu, D., Klein, C., Kastrissios, H., Miller, A. A., Hars, V., Hollis, D., Rosner, G., Powell, B., Ratain, M., and Larson, R. A. Two schedules of oral topotecan for myelodysplastic syndrome (MDS)-CALGB study 19803. Proc. Am. Soc. Clin. Oncol., 20: 303a, 2001.
25. Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., Ellerton, J., Larson, R. A., Schiffer, C. A., and Holland, J. F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group Br. J. Clin. Oncol., 20: 2429-2440, 2002.
26. Ellis, M., Zwaan, F., Hedstrom, U., Poynton, C., Kristenseb, J., Jumaa, P., Wassel, J., and al-Ramadi, B. Recombinant human interleukin 11 and bacterial infection in patients with hematological malignant disease undergoing chemotherapy: a double blind placebo-controlled randomized trial. Lancet, 361: 275-280, 2003.
27. Gerhartz, H. H., Marcus, R., Delmer, A., Zwierzina, H., Suciu, S., Dardenne, M., Solbu, G., de Witte, T., Jacobs, A., Visani, G., Fiere, D., Sonneveld, P., Labaar, B., Hoffbrand, A. V., Fenaux, P., Hayatt, M., Delousscher, L., Coiffier, B., Sizoo, W., Willemze, R., Ribiero, M., Mandelli, F., Burghouts, G., Cauchie, C. P. M., Roozendaal, K. I., Goudsmit, R., Doner, D., Castoldi, G. L., Stern, A., and Zittoun, R. A randomized Phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group. Leukemia (Baltimore), 8: 16-23, 1994.
28. Miller, K. B., Kim, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., O'Connell, M. J., and Kyungmann, K. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann. Hematol., 65: 162-168, 1992.
29. Cheson, B. D., Jasperse, D. M., Simon, R., and Friedman, M. A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J. Clin. Oncol., 4: 1857-1864, 1986.
30. Wijermans, P. W., Krulder, J. W., Huijgens, P. C., and Neve, P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia (Baltimore), 11: 1-5, 1997.